SLC2A1 and Its Related Epileptic Phenotypes

被引:1
|
作者
Patane, Francesca [1 ]
Pasquetti, Elisa [1 ]
Sullo, Federica [1 ]
Tosto, Monica [1 ]
Romano, Catia [2 ]
Salafia, Stefania [3 ]
Falsaperla, Raffaele [4 ,5 ]
机构
[1] Univ Catania, Dept Clin & Expt Med, Sect Pediat & Child Neuropsychiat, Pediat Postgrad Residency Program, Catania, Italy
[2] Italian Blind Union, Catania Sect, Catania, Italy
[3] Lentini Hosp, Unit Pediat, I-96016 Contrada Colle Roggio, Lentini, Italy
[4] Univ Hosp Policlin Rodolico San Marco, Unit Pediat & Pediat Emergency, Catania, Italy
[5] Univ Hosp Policlin Rodolico San Marco, Unit Neonatal Intens Care & Neonatol, Catania, Italy
关键词
SLC2A1; epilepsy; microcephaly; movement disorders; ketogenic diet; GLUT1 DEFICIENCY SYNDROME; CHILDHOOD NEUROFIBROMATOSIS TYPE-2; GLUCOSE-TRANSPORTER-1; DEFICIENCY; MEDICAL CURIOSITIES; ABSENCE EPILEPSY; NATURAL-HISTORY; TREATABLE CAUSE; KETOGENIC DIET; MUTATIONS; BRAIN;
D O I
10.1055/s-0041-1728668
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Glucose transporter type 1 deficiency syndrome (GLUT1DS) is caused by heterozygous, mostly de novo, mutations in SLC2A1 gene encoding the glucose transporter GLUT1, the most relevant energy transporter in the blood-brain barrier. GLUT1DS includes a broad spectrum of neurologic disturbances, from severe encephalopathy with developmental delay, to epilepsy, movement disorders, acquired microcephaly and atypical mild forms. For diagnosis, lumbar puncture and genetic analysis are necessary and complementary; an immediate response to ketogenic diet supports the diagnosis in case of high suspicion of disease and negative exams. The ketogenic diet is the first-line treatment and should be established at the initial stages of disease.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Metabolic reprogramming induced by inhibition of SLC2A1 suppresses tumor progression in lung adenocarcinoma
    Wang, Yanfen
    Shi, Shanshan
    Ding, Yongling
    Wang, Zheng
    Liu, Shuang
    Yang, Jiajia
    Xu, Tongpeng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (11): : 10759 - 10769
  • [42] A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect
    Paula Lopez-Serra
    Miguel Marcilla
    Alberto Villanueva
    Antonio Ramos-Fernandez
    Anna Palau
    Lucía Leal
    Jessica E. Wahi
    Fernando Setien-Baranda
    Karolina Szczesna
    Catia Moutinho
    Anna Martinez-Cardus
    Holger Heyn
    Juan Sandoval
    Sara Puertas
    August Vidal
    Xavier Sanjuan
    Eva Martinez-Balibrea
    Francesc Viñals
    Jose C. Perales
    Jesper B. Bramsem
    Torben F. Ørntoft
    Claus L. Andersen
    Josep Tabernero
    Ultan McDermott
    Matthew B. Boxer
    Matthew G. Vander Heiden
    Juan Pablo Albar
    Manel Esteller
    Nature Communications, 5
  • [43] Investigation of SLC2A1 gene variants in genetic generalized epilepsy patients with eyelid myoclonia
    Altiokka-Uzun, Gunes
    Ozdemir, Ozkan
    Ugur-Iseri, Sibel
    Bebek, Nerses
    Gurses, Candan
    Ozbek, Ugur
    Baykan, Betul
    EPILEPTIC DISORDERS, 2018, 20 (05) : 396 - 400
  • [44] Glycolysis-Related SLC2A1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy (vol 14, 5344, 2022)
    Zheng, Haosheng
    Long, Guojie
    Zheng, Yuzhen
    Yang, Xingping
    Cai, Weijie
    He, Shiyun
    Qin, Xianyu
    Liao, Hongying
    CANCERS, 2023, 15 (03)
  • [45] A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect
    Lopez-Serra, Paula
    Marcilla, Miguel
    Villanueva, Alberto
    Ramos-Fernandez, Antonio
    Palau, Anna
    Leal, Lucia
    Wahi, Jessica E.
    Setien-Baranda, Fernando
    Szczesna, Karolina
    Moutinho, Catia
    Martinez-Cardus, Anna
    Heyn, Holger
    Sandoval, Juan
    Puertas, Sara
    Vidal, August
    Sanjuan, Xavier
    Martinez-Balibrea, Eva
    Vinals, Francesc
    Perales, Jose C.
    Bramsem, Jesper B.
    Orntoft, Torben F.
    Andersen, Claus L.
    Tabernero, Josep
    McDermott, Ultan
    Boxer, Matthew B.
    Vander Heiden, Matthew G.
    Pablo Albar, Juan
    Esteller, Manel
    NATURE COMMUNICATIONS, 2014, 5
  • [46] Absence of Mutation in the SLC2A1 Gene in a Cohort of Patients with Alternating Hemiplegia of Childhood (AHC)
    Vuillaumier-Barrot, S.
    Panagiotakaki, E.
    Le Bizec, C.
    El Baba, C.
    Fontaine, B.
    Arzimanoglou, A.
    Seta, N.
    Nicole, S.
    NEUROPEDIATRICS, 2010, 41 (06) : 267 - 269
  • [47] Targeting SLC2A1 and SLC38A2-mediated metabolic shift in SMARCA4/A2-dual deficient cancer
    Zhu, Xianbing
    Fu, Zheng
    Chen, Shary
    Ong, Dionzie
    Aceto, Giulio
    Ho, Rebecca
    Steinberger, Jutta
    Li, Eunice
    Huntsman, David
    Foulkes, William
    Huang, Sidong
    Wang, Yemin
    CANCER RESEARCH, 2023, 83 (07)
  • [48] Early-onset absence epilepsy: SLC2A1 gene analysis and treatment evolution
    Agostinelli, S.
    Traverso, M.
    Accorsi, P.
    Beccaria, F.
    Belcastro, V.
    Capovilla, G.
    Cappanera, S.
    Coppola, A.
    Dalla Bernardina, B.
    Darra, F.
    Ferretti, M.
    Elia, M.
    Galeone, D.
    Giordano, L.
    Gobbi, G.
    Nicita, F.
    Parisi, P.
    Pezzella, M.
    Spalice, A.
    Striano, S.
    Tozzi, E.
    Vignoli, A.
    Minetti, C.
    Zara, F.
    Striano, P.
    Verrotti, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2013, 20 (05) : 856 - 859
  • [49] SLC2A1 mutations are a rare cause of pediatric-onset hereditary spastic paraplegia
    Nicita, Francesco
    Schirinzi, Tommaso
    Stregapede, Fabrizia
    Vasco, Gessica
    Bertini, Enrico
    Trauaglini, Lorena
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2019, 23 (02) : 329 - 332
  • [50] VEGFA and SLC2A1 are prognostic biomarkers for patients with resectable colorectal cancer liver metastases
    Goos, Jeroen A. C. M.
    de Cuba, Erienne M. V.
    Coupe, Veerle M. H.
    Diosdado, Begona
    Delis-van Diemen, Pien M.
    Karga, Cemile
    Belien, Jeroen A. M.
    van Oordt, C. Willemien Menke-Van der Houven
    Geldof, Albert A.
    Meijer, Gerrit A.
    Hoekstra, Otto S.
    Fijneman, Remond J. A.
    CANCER RESEARCH, 2015, 75